Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alaris Royalty ( ($TSE:AD.UN) ) has issued an update.
Alaris Equity Partners has announced a $75 million bought deal offering of 6.25% convertible unsecured senior debentures, alongside a US$30 million investment into a new partner, Renovo Medical Group, LLC. The proceeds from the debenture offering will be used to repay outstanding debts and fund future investments, potentially strengthening Alaris’s financial position and expanding its investment portfolio.
The most recent analyst rating on ($TSE:AD.UN) stock is a Buy with a C$27.00 price target. To see the full list of analyst forecasts on Alaris Royalty stock, see the TSE:AD.UN Stock Forecast page.
Spark’s Take on TSE:AD.UN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AD.UN is a Outperform.
Alaris Royalty’s strong financial performance, characterized by robust profitability and a healthy balance sheet, is a key strength. The stock appears undervalued with a high dividend yield, appealing to income investors. Despite limited technical momentum, recent strategic investments and consistent distributions bolster confidence in future growth. Overall, the stock presents a stable investment opportunity with potential upside from strategic initiatives.
To see Spark’s full report on TSE:AD.UN stock, click here.
More about Alaris Royalty
Alaris Equity Partners is a company involved in providing equity capital to private businesses, focusing on generating stable cash flows and long-term growth. The company operates in the financial sector, primarily engaging in investments and partnerships with businesses across various industries.
Average Trading Volume: 74,460
Technical Sentiment Signal: Buy
Current Market Cap: C$912.2M
For an in-depth examination of AD.UN stock, go to TipRanks’ Overview page.